Innoviva Profit Margin 2010-2024 | INVA

Current and historical gross margin, operating margin and net profit margin for Innoviva (INVA) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Innoviva net profit margin as of December 31, 2024 is 18.31%.
Innoviva Annual Profit Margins
Innoviva Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.132B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $835.717B 67.80
Novo Nordisk (NVO) Denmark $406.526B 27.53
Johnson & Johnson (JNJ) United States $394.223B 16.39
AbbVie (ABBV) United States $360.274B 20.17
Roche Holding AG (RHHBY) Switzerland $264.748B 0.00
Merck (MRK) United States $230.880B 11.95
Novartis AG (NVS) Switzerland $223.246B 13.98
Pfizer (PFE) United States $151.025B 8.57
Sanofi (SNY) $136.409B 12.92
Bayer (BAYRY) Germany $23.028B 3.69